☆ 4.7 Article

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study

Vivek Naranbhai et al.

Summary: This study aimed to determine the effect of HLA-A*03 as a biomarker for predicting response to immunotherapy. The results showed that the HLA-A*03 gene was associated with reduced overall survival after immunotherapy and this effect was observed across different types of immunotherapy agents and tumor types.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

Robert J. Motzer et al.

Summary: The study found that biomarkers previously associated with immune checkpoint inhibitor-containing regimens were not predictive for survival in RCC patients treated with nivolumab plus ipilimumab. However, gene expression analysis revealed an association between an inflammatory response and progression-free survival in patients receiving this treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Matthew D. Tucker et al.

Summary: This study reviewed 110 patients with clear cell mRCC and found that a lower baseline NER was associated with improved clinical outcomes (PFS, OS, and ORR) in patients treated with nivolumab plus ipilimumab.

BIOMARKER RESEARCH (2021)

Add to Collection

Article Oncology

Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response

Sarabjot Pabla et al.

Summary: The study identified a tumor immunogenic signature (TIGS) using RNA analysis, categorizing tumors into strong, moderate, and weak based on immune response, which can predict the clinical benefit of immune checkpoint inhibitors. Strong TIGS tumors showed higher ICI response rates and improved survival, with a stronger correlation with highly proliferative tumors.

BIOMARKER RESEARCH (2021)

Add to Collection

Article Oncology

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Jean-Fran Comma Cois Martini et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer et al.

NATURE MEDICINE (2020)

Add to Collection

Article Oncology

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

Robert J. Motzer et al.

CANCER CELL (2020)

Add to Collection

Article Oncology

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

Tian Zhang et al.

ONCOIMMUNOLOGY (2020)

Add to Collection

Article Oncology

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients

Sarabjot Pabla et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Meeting Abstract Oncology

Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Toni K. Choueiri et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Effect of CTLA-4 overexpression on response to ipilimumab in melanoma.

Mary Nesline et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Pathology

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors

Jeffrey M. Conroy et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott et al.

NATURE MEDICINE (2018)

Add to Collection

Article Oncology

LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

B I Rini et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Review Oncology

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer

Reinhard Buttner et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Review Immunology

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

Nicholas A. Manieri et al.

TRENDS IN IMMUNOLOGY (2017)

Add to Collection

Article Oncology

CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases

Erna-Elise Paulsen et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)

Add to Collection

Review Immunology

The regulation of immune tolerance by FOXP3

Ling Lu et al.

NATURE REVIEWS IMMUNOLOGY (2017)

Add to Collection

Article Hematology

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky et al.

BLOOD (2013)

Add to Collection

Review Biochemistry & Molecular Biology

NKG2D ligands in tumor immunity

N. Nausch et al.

ONCOGENE (2008)

Add to Collection

Article Medicine, General & Internal

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

S Paik et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.